Login to Your Account

Other News To Note

Tuesday, June 19, 2012
• Forma Therapeutics, of Watertown, Mass., and TGen Drug Development, of Scottsdale, Ariz., a subsidiary of the Phoenix-based Translational Genomics Research Institute, agreed to jointly develop transformative cancer therapies. Forma targets essential cancer pathways to create small-molecule cancer therapies. TGen will bring preclinical and clinical development capabilities to Forma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription